DrugPatentWatch Database Preview

Details for Patent: 9,616,096

« Back to Dashboard

Which drugs does patent 9,616,096 protect, and when does it expire?

Patent 9,616,096 protects QBRELIS and is included in one NDA.

This patent has seven patent family members in seven countries.

Summary for Patent: 9,616,096

Title:	Lisinopril formulations
Abstract:	Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
Inventor(s):	Mosher; Gerold L. (Kansas City, MO), Miles; David W. (Kansas City, MO)
Assignee:	SILVERGATE PHARMACEUTICALS, INC. (Greenwood Village, CO)
Application Number:	15/268,095
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 9,616,096

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Azurity	QBRELIS	lisinopril	SOLUTION;ORAL	208401-001	Jul 29, 2016		RX	Yes	Yes						TREATMENT OF HYPERTENSION
Azurity	QBRELIS	lisinopril	SOLUTION;ORAL	208401-001	Jul 29, 2016		RX	Yes	Yes						REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION
Azurity	QBRELIS	lisinopril	SOLUTION;ORAL	208401-001	Jul 29, 2016		RX	Yes	Yes						METHOD OF TREATING HYPERTENSION
Azurity	QBRELIS	lisinopril	SOLUTION;ORAL	208401-001	Jul 29, 2016		RX	Yes	Yes						TREATMENT OF HEART FAILURE
Azurity	QBRELIS	lisinopril	SOLUTION;ORAL	208401-001	Jul 29, 2016		RX	Yes	Yes						TREATMENT OF MYOCARDIAL INFARCTION
Azurity	QBRELIS	lisinopril	SOLUTION;ORAL	208401-001	Jul 29, 2016		RX	Yes	Yes						ACUTE MYOCARDIAL INFARCTION

International Family Members for US Patent 9,616,096

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	3003274
China	108472252
European Patent Office	3368012
Hong Kong	1258803
Japan	2018533583
South Korea	20180069907